November 9, 2021

**National Stock Exchange of India Ltd.**
Exchange Plaza,
C1, Block G,
Bandra Kurla Complex,
Bandra (East),
**Mumbai - 400 051.**

**Kind Attn. Mr. Binoy Yohannan**

***Dear Sir,***

This has reference to your letter no. NSE/CM/Surveillance/11294 dated November 8, 2021.

We refer to the news item which appeared on the 'Website-www.economictimes.com' dated November 7, 2021, regarding recall of Gatifloxacin Ophthalmic Solution bottles by the Company in the US market.

The Company has voluntarily recalled specific batches of Gatifloxacin Ophthalmic Solution, 0.5% to the retail level. This recall does not have a material impact on the revenues or profitability of the Company.

Lupin remains deeply committed to manufacture high-quality medicines for patients. We take our obligations seriously and have rigorous quality systems in place to ensure compliance with stringent regulatory requirements.

We would like to state that the Company has always promptly intimated the Stock Exchanges about material events within the timelines prescribed by the Listing Regulations.

Thanking you,

**For LUPIN LIMITED**

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal, 2.5.4.20=e8a002ede68da3b7e41e01d21c2b9062761a29a5f00491762a5ac549cb034cae, postalCode=400104, st=Maharashtra, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdb67a2ff09c4242771b2a, cn=Rajvardhan Vishnu Satam
Date: 2021.11.09 09:55:23 +05'30'

**R. V. SATAM**
**COMPANY SECRETARY**
**(ACS - 11973)**